TheConversation: Despite killing a majority of people it infects, some patients
survive the onslaught of Ebola virus. What gives them this resistance,
ask Michael Katze, professor of microbiology, and colleagues from the
University of Washington in a study published in the journal Science
They used mice to answer this question because despite being infected
with Ebola virus, they don’t show the symptoms seen in Ebola-infected
humans. Mice tend to be a good animal model for scientists to understand
human diseases, because they are easy to handle in labs and have been
studied extensively. However, in the case of Ebola, it is their apparent
resistance which may give us more useful answers.
Katze and his colleagues cross-bred different genetic varieties of
lab-bred mice to produce a strain that did fall victim to Ebola.
Although the virus grows in both susceptible and disease-resistant mice,
it grows to lower levels in resistant mice. The pattern of infection
differs too. For example, virus infection of the liver is restricted to
only certain types of cells in resistant mice rather than infecting most
liver cells as seen in the susceptible mice.
Analysis of the mouse strains showed that the resistance was linked
with differences in the expression of a number of mouse genes. If virus
resistance is genetic in mice, could our susceptibility to fatal virus
infections, such as Ebola, be determined by a genetic predisposition?
What about viruses that only rarely cause fatal infections? Does a
difference in genetic susceptibility also explain why some people get
regular respiratory virus infections, while others rarely complain of
infection?
The answer is a qualified yes, but it is not as startling as it first
appears. Katze and colleagues show for the first time that resistance
to Ebola is due to differences in gene expression. This will come as no
great surprise to most virologists, who have long accepted that animals
are not simply passive victims of infection but can actually contribute
to diseases when infected. This has been seen in many different kinds of
animals.
It is clear that the first line of defence following infection – the
innate immune response that is present in all cells of the body – is key
to the outcome. In Katze’s study, many of the genes they identify are
implicated in the generation and maintenance of the integrity of blood
vessels. Disruption of these gene functions correlate with the known
symptoms of Ebola, such as haemmorhage, and presumably reflect
differences in the way that the genes are expressed and regulated in
different genetic backgrounds.
However, caution is needed in reading too much into the results. The
fact that cross-bred mice respond with a range of symptoms after Ebola
infection – just like humans do – may not be due to a genetic cause. For
example, humans are more genetically mixed than mice and the sheer
number of genetic combinations are likely to produce a graded spectrum
of responses rather than a distinct division as seen in the mouse
strains studied.
Equally important – but not addressed by the study – is the potential
role of environmental factors that undoubtedly also play a role in the
disease process. These include factors such as the underlying health
status of the at-risk population,the virus dose encountered and the
route of exposure. While the data in this study suggest a genetic link
with Ebola virus, more work is required to confirm the role of these
genes. In particular it will be important to study animals which have
defects in their genes to see if they display Ebola symptoms.
Despite these caveats the study does raise some intriguing and
potentially valuable prospects. The wild-type virus caused no symptoms
and appears not to replicate in mice. So the study used a mouse-adapted
strain of Ebola virus. The genetic differences between the two types of
virus will enable the molecular basis of this difference to be explored
in detail. Ebola is known to infect mammals other than primates, for
example bats and duiker, and the changes in the virus required to infect these hosts can now be investigated.
What is perhaps most interesting is that mice with only low levels of
virus production did not experience severe disease. This suggests that
it may not be necessary to completely eliminate the virus from the body
to provide protection against the disease. So treatments or
interventions designed to reduce virus levels, rather than eradicate it,
may be sufficient to alleviate the considerable suffering we see in
many Ebola patients. If this proves to be the case then the hurdle to be
surmounted for therapies may be lower than initially thought. This is good news for the vaccines now being tested.